Comparison between Akums Drugs IPO and Orient Technologies IPO.
Akums Drugs IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Orient Technologies IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Akums Drugs IPO is up to ₹1,856.74 Cr whereas the issue size of the Orient Technologies IPO is up to ₹214.76 Cr. The final issue price of Akums Drugs IPO is ₹679.00 per share and of Orient Technologies IPO is ₹206.00 per share.
| Akums Drugs IPO | Orient Technologies IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ₹646.00 per share | ₹195.00 per share |
| Issue Price (Upper) | ₹679.00 per share | ₹206.00 per share |
| Issue Price (Final) | ₹679.00 per share | ₹206.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹64.00 per share | |
| Market Lot Size | 22 shares | 72 shares |
| Fresh Issue Size | 1,00,37,708 shares | 58,25,242 shares |
| Fresh Issue Size (Amount) | up to ₹680.99 Cr | up to ₹120.00 Cr |
| OFS Issue Size | 1,73,30,435 shares | 46,00,000 shares |
| OFS Issue Size (Amount) | up to ₹1,175.75 Cr | up to ₹94.76 Cr |
| Issue Size Total | 2,73,68,143 shares | 1,04,25,242 shares |
| Issue Size Total (Amount) | up to ₹1,856.74 Cr | up to ₹214.76 Cr |
Akums Drugs IPO opens on Jul 30, 2024, while Orient Technologies IPO opens on Aug 21, 2024. The closing date of Akums Drugs IPO and Orient Technologies IPO is Aug 01, 2024, and Aug 23, 2024, respectively.
| Akums Drugs IPO | Orient Technologies IPO | |
|---|---|---|
| Anchor Bid Date | Jul 29, 2024 | Aug 20, 2024 |
| Issue Open | Jul 30, 2024 | Aug 21, 2024 |
| Issue Close | Aug 01, 2024 | Aug 23, 2024 |
| Basis Of Allotment (Tentative) | Aug 02, 2024 | Aug 26, 2024 |
| Initiation of Refunds (Tentative) | Aug 05, 2024 | Aug 27, 2024 |
| Credit of Share (Tentative) | Aug 05, 2024 | Aug 27, 2024 |
| Listing date (Tentative) | Aug 06, 2024 | Aug 28, 2024 |
| Anchor Lockin End date 1 | Sep 01, 2024 | Sep 24, 2024 |
| Anchor Lockin End date 2 | Oct 31, 2024 | Nov 23, 2024 |
Akums Drugs IPO P/E ratio is , as compared to Orient Technologies IPO P/E ratio of 17.8.
| Akums Drugs IPO | Orient Technologies IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 82.48 | 97.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 75.29 | 73.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 17.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹857.82 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 0.11% | 27.26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 3.37% | 28.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹11.57 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | -0.57 | 23.64 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Akums Drugs IPO Retail Individual Investors (RII) are offered 27,12,424 shares while in Orient Technologies IPO retail investors are offered 27,12,424 shares. Qualified Institutional Buyers (QIB) are offered 81,37,276 shares in Akums Drugs IPO and 20,85,048 shares in Orient Technologies IPO.
| Akums Drugs IPO | Orient Technologies IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,22,05,912 shares | 31,27,572 shares |
| Market Maker Reservation | ||
| QIB | 81,37,276 shares | 20,85,048 shares |
| NII | 40,68,637 shares | 15,63,787 shares |
| RII | 27,12,424 shares | 36,48,835 shares |
| Employee | 2,43,902 shares | |
| Others | ||
| Total | 2,73,68,151 shares | 1,04,25,242 shares |
Akums Drugs IPO subscribed 63.44x in total, whereas Orient Technologies IPO subscribed 154.84x.
| Akums Drugs IPO | Orient Technologies IPO | |
|---|---|---|
| QIB (times) | 90.09x | 188.79x |
| NII (times) | 42.10x | 310.03x |
| Big NII (times) | 47.43x | 343.45x |
| Small NII (times) | 31.45x | 243.20x |
| RII (times) | 20.80x | 68.93x |
| Employee (times) | 4.14x | |
| Other (times) | ||
| Total (times) | 63.44x | 154.84x |
